The U.S. Supreme Court’s recent decision to overturn the Chevron doctrine, which had long provided deference to federal agencies in interpreting their own regulations, is poised to have significant repercussions across various sectors. Legal professionals, particularly those involved in medical research, should be aware of the potential effects on regulatory processes and the adoption of artificial intelligence (AI) technologies. As highlighted by Ragini Acharya and Matthew Deutsch at Husch Blackwell, the ruling might impede agencies’ regulatory efforts, thereby slowing down the approval and implementation of AI-driven methodologies in medical research and possibly affecting regulators’ responses to public health emergencies. The detailed analysis of this development can be explored at Law360.